Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1h-pyrazol-4-yl)-1h-(1,2,3)triazolo(4,5-b)pyrazine
2. Azd6094
3. Hmpl-504
4. Volitinib
1. Volitinib
2. 1313725-88-0
3. Azd-6094
4. Hmpl-504
5. Azd6094
6. Savolitinib [inn]
7. Hmpl504
8. (s)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1h-pyrazol-4-yl)-1h-[1,2,3]triazolo[4,5-b]pyrazine
9. Chembl3334567
10. 2a2da6857r
11. 1h-1,2,3-triazolo(4,5-b)pyrazine, 1-((1s)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1h-pyrazol-4-yl)-
12. 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine
13. Orpathys
14. Unii-2a2da6857r
15. Azd6094, Hmpl-504
16. Volitinib(savolitinib)
17. Azd-6094volitinib
18. Savolitinib (usan/inn)
19. Savolitinib [usan:inn]
20. Savolitinib [usan]
21. Savolitinib [who-dd]
22. Gtpl9918
23. Hmpl 504
24. Schembl12489208
25. Ex-a845
26. Dtxsid801111016
27. Azd 6094
28. Bdbm50023342
29. Mfcd28359096
30. Nsc782121
31. Nsc800966
32. S7674
33. Akos030526403
34. Savolitinib(azd6094, Hmpl-504)
35. Zinc149738712
36. Ccg-267976
37. Db12048
38. Nsc-782121
39. Nsc-800966
40. Compound 28 [pmid: 25148209]
41. Ncgc00475727-01
42. Ac-35267
43. As-35250
44. Bv160378
45. Hy-15959
46. Savolitinib;volitinib;hmpl-504;azd-6094
47. A14419
48. D11139
49. J-690125
50. Q27254463
51. (3e)-5-chloro-3-[(5-{3-[(4-methyl-1,4-diazepan-1-yl)carbonyl]phenyl}-2-furyl)methylene]-1,3-dihydro-2h-indol-2-one Hydrochloride
52. 1-((s)-1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1h-pyrazol-4-yl)-1h-(1,2,3)-triazolo(4,5-b)pyrazine
53. 4-{1-[(1s)-1-{imidazo[1,2-a]pyridin-6-yl}ethyl]-1h-[1,2,3]triazolo[4,5-b]pyrazin-6-yl}-1-methyl-1h-pyrazole
| Molecular Weight | 345.4 g/mol |
|---|---|
| Molecular Formula | C17H15N9 |
| XLogP3 | 1.5 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 3 |
| Exact Mass | 345.14504152 g/mol |
| Monoisotopic Mass | 345.14504152 g/mol |
| Topological Polar Surface Area | 91.6 Ų |
| Heavy Atom Count | 26 |
| Formal Charge | 0 |
| Complexity | 505 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of lung cancer
Treatment of renal neoplasms
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
ABOUT THIS PAGE
A Savolitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Savolitinib, including repackagers and relabelers. The FDA regulates Savolitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Savolitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Savolitinib supplier is an individual or a company that provides Savolitinib active pharmaceutical ingredient (API) or Savolitinib finished formulations upon request. The Savolitinib suppliers may include Savolitinib API manufacturers, exporters, distributors and traders.
Savolitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Savolitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Savolitinib GMP manufacturer or Savolitinib GMP API supplier for your needs.
A Savolitinib CoA (Certificate of Analysis) is a formal document that attests to Savolitinib's compliance with Savolitinib specifications and serves as a tool for batch-level quality control.
Savolitinib CoA mostly includes findings from lab analyses of a specific batch. For each Savolitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Savolitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Savolitinib EP), Savolitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Savolitinib USP).
LOOKING FOR A SUPPLIER?
